Please call the Pharmacy Medicines Unit on or for a copy.

Size: px
Start display at page:

Download "Please call the Pharmacy Medicines Unit on or for a copy."

Transcription

1

2 Title: PATIENT GROUP DIRECTION FOR THE SUPPLY OF FLUCONAZOLE 150MG UNDER THE MINOR AILMENT SERVICE Identifier: Across NHS Boards Organisation Wide Directorate Clinical Service Sub Department Area This controlled document shall not be copied in part or whole without the express permission of the author or the author s representative. Review date: July 2008 Author: Policy application: Alison Strath Scottish Executive NHS Scotland Caroline Hind NHS Grampian NHS Grampian Purpose: This Patient Group Direction (PGD) authorises appropriately qualified Community Pharmacists registered as members of the Royal Pharmaceutical Society to supply fluconazole to individuals without the requirement for a patient specific prescription written by a medical practitioner. Responsibilities for implementation: Organisational: Local Policy statement: Review: NHS Grampian Pharmacy Medicines Unit Community pharmacy contractors It is the responsibility of individual pharmacists and their managers (where applicable) to ensure that they work with the terms laid down in this PGD and that pharmacists using this PGD act within their own level of competence. This policy will be reviewed in two years or sooner if current treatment recommendations change. This policy is also available in large print and on computer disk. Other formats can be supplied on request. Please call the Pharmacy Medicines Unit on or for a copy.

3 PATIENT GROUP DIRECTION FOR THE SUPPLY OF FLUCONAZOLE 150MG UNDER THE MINOR AILMENT SERVICE A Patient Group Direction is a specific written instruction for the supply or administration of named medicines in an identified clinical situation. It is drawn up locally by Doctors, Pharmacists and other appropriate professionals, approved by the Employer and advised by the relevant professional advisory committees. In most cases, appropriate clinical care is provided on an individual basis by a specific prescriber to a specific individual patient. Patient Group Directions should only be considered where they offer a benefit to patient care without compromising patient safety in any way. Effective from 1 st July 2006 Review date July 2008

4 PATIENT GROUP DIRECTION FOR THE SUPPLY OF FLUCONAZOLE 150MG UNDER THE MINOR AILMENT SERVICE 1 Introduction This patient group direction (PGD) is designed to guide pharmacists on the supply of fluconazole under the Minor Ailment Service (MAS). This will allow pharmacists to dispense a POM pack of fluconazole under PGD. Candidiasis is a yeast infection caused by the Candida species of fungus, usually Candida albicans. Many women are affected by vaginal thrush at some point in their lives and in some women it may recur regularly. The condition develops when Candida albicans, which is often present in the vagina, causes itching, irritation, redness, soreness and swelling of the vagina and vulva and a thick, white vaginal discharge. 2 Clinical Decision Making 2.1 Patients who may be considered for the supply of fluconazole Women with previous history of vaginal candidiasis presenting in Community Pharmacy with a need for treatment of symptoms of vaginal candidiasis, and registered for the Minor Ailment Service (MAS). 2.2 Patients who may receive the supply of fluconazole All patients in 2.1 above, who do not want specifically to consult a doctor and are willing to have treatment from the pharmacist. Women over 16 years of age and under 60 years of age. 2.3 Consent Prior to the supply of fluconazole, consent must be obtained from the patient. There is no legal requirement for consent to be in writing but written consent does serve to provide a permanent record that the individual (patient, parent or guardian) has been informed about the process, benefits and risks of fluconazole. Individuals (patient, parent or guardian) should also be informed about how data will be stored, who will be able to access that information and how that data may be used. If a patient s fitness and suitability cannot be established, supply should be deferred and the patient referred to their doctor. Written and verbal information should be available in a form that can be easily understood by the person who will be giving the consent. Where English is not easily understood, translations and properly recognised interpreters should be used.

5 2.4 Consent for supply to children. Not applicable This PGD cannot be used to supply to patients under 16 years of age. 2.5 Contraindications Patients may not receive a supply of fluconazole if they are: Women who are experiencing the symptoms for the first time. Women with a history of liver or kidney disease. At risk of sexually transmitted infection (STI) or other cause for vaginal discharge. Experiencing irregular or abnormal vaginal bleeding. Experiencing genital ulceration. Known to have a hypersensitivity to fluconazole or any of the components of the capsule. Pregnant. Breast-feeding. A known diabetic with recurring candidiasis Presenting for a second request within one month. Presenting with vaginal pain, bleeding or blistering. Are known to have more than two infections of thrush within the last six months. 2.6 Patient Referral Urgent referral: Not applicable Routine referral: If symptoms not clearing within 3 days Pregnant Breast-feeding Renal impairment Known diabetic and recurring candidiasis Second request within one month Vaginal pain, bleeding or blistering 2.7 Action to be taken when a patient is excluded from treatment under this PGD Patients should be referred to their doctor where they are excluded from treatment in 2.5 but also if symptoms have not cleared within 3 days. 2.8 Action to be taken when a patient does not wish to receive treatment under this PGD The patient should be referred to their doctor. 2.9 Concurrent medication Not applicable.

6 3 Designated Staff Authorised to supply fluconazole Community Pharmacists registered as members of the Royal Pharmaceutical Society of Great Britain are authorised to use the PGD for the supply of fluconazole under the Minor Ailments Service. It is important to note that the above professionals may only supply or administer medicines under a PGD as named individuals. In addition the following requirements are necessary. Staff must: agree to be professionally accountable for their work (Appendix 1). be aware of current treatment recommendations. have appropriate experience and competence to identify and recommend treatment for vaginal candidiasis. have access to the current PGD for fluconazole 150mg under the Minor Ailments Service. maintain their skills and knowledge in this area according to their individual Code of Professional Conduct. agree to work within the terms of the NHS Grampian PGD. The Director of Pharmacy and Medicines Management will be responsible for: Ensuring that the current PGD for fluconazole is available to community pharmacists providing care under this direction. Maintaining a current record of all pharmacists authorised to supply fluconazole under this PGD. 4 Description of Treatment Available Under this Direction 4.1 Presentation Fluconazole 150mg capsule (non-proprietary) single-capsule pack Description and excipients can vary with manufacturer Fluconazole is a Prescription Only Medicine (POM). 4.2 Dose, route and frequency For the treatment of Vaginal candidiasis a single dose of 150mg by mouth. One capsule completes the course.

7 4.3 Adverse effects Occasional: nausea, abdominal discomfort, diarrhoea, flatulence, headache, rash. Rare: dyspepsia, vomiting, taste disturbance, hepatic disorders, hypersensitivity reactions, anaphylaxis, dizziness, seizures, alopecia, pruritus, toxic epidermal necrolysis, Stevens-Johnston syndrome, hyperlipidaemia, leucopenia, thrombocytopenia, hypokalaemia. Also see current BNF. In the event of a Suspected Adverse Drug Reaction, please complete a Yellowcard and submits to the MHRA. A Yellowcard can be found at the rear of the BNF. Record findings, advice and actions in person s record Medical advice in cases of anaphylaxis. 4.4 Advice to patient Medical advice must be sought as soon as possible from a doctor if any patient develops any signs of hypersensitivity. If there is a delay in medical support arriving and the condition of the patient is deteriorating then an emergency ambulance must be called on 999. Provide Patient Information Leaflet. Treat at any time of menstrual cycle, including during periods. Discuss any possible side-effects with the patient. Advice regarding re-infection and that partner may need treatment if symptomatic. Washing the vaginal area with water only, avoiding the use of perfumed soaps, vaginal deodorants or douches. Avoiding using latex condoms, spermicidal creams and lubricants if they cause irritation. Wearing cotton underwear and loose-fitting clothes if possible. 4.5 Follow up treatment Not applicable 5 Documentation 5.1 Authorisation of supply under PGD The following staff are authorised to supply fluconazole without a medical prescription providing the patient falls into one of the categories listed in 2.2 of this PGD. Staff must be employed either directly by NHS Grampian, or contracted to provide NHS services, or providing services in partnership with NHS Grampian under the direction of this authorised PGD. Registered pharmacists as recognised by RPSGB

8

9 Appendix 1 HEALTH CARE PROFESSIONAL AGREEMENT TO SUPPLY MEDICINES UNDER PATIENT GROUP DIRECTION I: Based at: agree to supply medicines under the direction contained within the following Patient Group Direction PATIENT GROUP DIRECTION FOR THE SUPPLY OF FLUCONAZOLE 150MG UNDER THE MINOR AILMENT SERVICE I have completed the appropriate training to my professional standards enabling me to supply medicines under the above Patient Group Direction. I agree not to act beyond my professional competence nor outwith the recommendations of the Patient Group Direction. Signed: Print name: Date: RPSGB No

10 Appendix 2 CERTIFICATE OF COMPETENCE TO SUPPLY MEDICINES UNDER PATIENT GROUP DIRECTION This authorises: Based at: To supply medicines under the following Patient Group Direction PATIENT GROUP DIRECTION FOR THE SUPPLY OF FLUCONAZOLE 150MG UNDER THE MINOR AILMENT SERVICE The above named person has satisfied the training requirements and is competent to supply medicines under the above Patient Group Direction. The above named person has agreed not to act beyond their professional competence nor outwith the recommendations of the Patient Group Direction Signed: Professor George Downie Director of Pharmacy and Medicines Management Date:

Job Title Name Signature Date

Job Title Name Signature Date Supply of Fluconazole 150mg capsule by Community Pharmacists working in Forth Valley Pharmacies under NHS Minor Ailment Service. Protocol Number 125 Version 5 Date protocol prepared: November 2014 Date

More information

xrfslt \j,3 0+ {6^1 Otc(L!?i:lr+ NHS FIFE PRIMARY CARE THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED BY:

xrfslt \j,3 0+ {6^1 Otc(L!?i:lr+ NHS FIFE PRIMARY CARE THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED BY: NHS FIFE PRIMARY CARE Patient Group Direction for Named Nurses in Contraception and Sexual Health Clinics to Supply Clotrim azole lo/o cream TO WOMEN CLIENTS for use in the treatment of vaginal candidiasis

More information

Consultation Group: See relevant page in the PGD. Review Date: October 2015

Consultation Group: See relevant page in the PGD. Review Date: October 2015 Patient Group Direction For The Supply Of Trimethoprim For The Treatment Of Women With Uncomplicated Urinary Tract Infections By Nurses And Pharmacists Working Within NHS Grampian Community Pharmacies

More information

Consultation Group: See relevant page in the PGD. Review Date: October 2016

Consultation Group: See relevant page in the PGD. Review Date: October 2016 Patient Group Direction For The Administration Of Adrenaline (Epinephrine) By Trained Nurses In The Management Of Cardiac Arrest In The Medical High Dependency Unit/Coronary Care Unit (MHDU/CCU) Working

More information

Name Job Title Signed Date. This Patient Group Direction is operational from: Oct 2017 Review date: Aug 19. Expires on 31 st October 2019

Name Job Title Signed Date. This Patient Group Direction is operational from: Oct 2017 Review date: Aug 19. Expires on 31 st October 2019 PGD4017 PATIENT GROUP DIRECTION FOR THE SUPPLY OF ACICLOVIR TABLETS FOR THE TREATMENT OF GENITAL HERPES SIMPLEX INFECTIONS by registered nurses and midwives in Integrated Sexual Health services employed

More information

Name Job Title Signed Date

Name Job Title Signed Date PGD3517 PATIENT GROUP DIRECTION FOR THE SUPPLY OF AZITHROMYCIN TABS/CAPS 250mg or TABS 500mg OR SUSPENSION 600mg/15mL FOR UNCOMPLICATED GENITAL CHLAMYDIA TRACHOMATIS, UNCOMPLICATED NEISSERIA GONORRHOEA

More information

Patient Group Direction for ACICLOVIR (Version 02) Valid From 1 October September 2019

Patient Group Direction for ACICLOVIR (Version 02) Valid From 1 October September 2019 Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history

More information

THE TREATMENT OF BACTERIAL VAGINOSIS (BV) OR TRICHOMONAS VAGINALIS

THE TREATMENT OF BACTERIAL VAGINOSIS (BV) OR TRICHOMONAS VAGINALIS PGD3717 PATIENT GROUP DIRECTION FOR THESUPPLY OF METRONIDAZOLE 400mg TABLETSFOR THE TREATMENT OF BACTERIAL VAGINOSIS (BV) OR TRICHOMONAS VAGINALIS (TV) by registered nurses and midwives in Integrated Sexual

More information

PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG CAPSULES / TABLETS FOR THE FIRST- LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION

PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG CAPSULES / TABLETS FOR THE FIRST- LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION This Patient Group Direction () must only be used by registered pharmacists who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version

More information

NHS Lothian Patient Group Direction Version: 001

NHS Lothian Patient Group Direction Version: 001 PATIENT GROUP DIRECTION FOR THE SUPPLY OF FUSIDIC ACID CREAM 2% TO TREAT MINOR STAPHYLOCOCCAL SKIN INFECTIONS (IMPETIGO) IN PATIENTS AGED OVER 2 YEARS BY PHARMACISTS WORKING WITHIN NHS LOTHIAN COMMUNITY

More information

Document Details. Patient Group Direction

Document Details. Patient Group Direction Document Details Title Patient Group Direction (PGD) CO-CODAMOL 30/500 TABLETS FOR MINOR INJURIES UNITS Trust Ref No 1956-35206 Local Ref (optional) Main points the document treatment of moderate pain

More information

PROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines

PROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines PROTOCOL FOR THE ADMINISTRATION OF SENNA Formulary and Prescribing Guidelines Introduction This protocol allows for the administration of Senna by a registered nurse without a prescription from a doctor

More information

Patient Group Direction For the supply of Fusidic Acid 2% Cream

Patient Group Direction For the supply of Fusidic Acid 2% Cream Patient Group Direction For the supply of Fusidic Acid 2% Cream This Patient Group Direction (PGD) is a specific written instruction for the supply of Fusidic Acid 2% Cream to groups of patients who may

More information

Supply of Fusidic Acid Cream 2% by Community Pharmacists for the treatment of impetigo in patients 2 years of age and over.

Supply of Fusidic Acid Cream 2% by Community Pharmacists for the treatment of impetigo in patients 2 years of age and over. Supply of Fusidic Acid Cream 2% by Community Pharmacists for the treatment of impetigo in patients 2 years of age and over. November 2017 Review Nov 2019 Signatures of those developing the Patient Group

More information

PATIENT GROUP DIRECTION

PATIENT GROUP DIRECTION PATIENT GROUP DIRECTION FOR THE SUPPLY OF FUSIDIC ACID CREAM 2% FOR THE TREATMENT OF IMPETIGO BY COMMUNITY PHARMACISTS UNDER THE PHARMACY FIRST SERVICE IN NHS HIGHLAND THE COMMUNITY PHARMACIST SEEKING

More information

Patient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders.

Patient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders. Patient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders. This document authorises the supply of Fusidic Acid Cream 2% by registered

More information

Patient Group Direction for Aspirin 300mg Version: 02 Start Date: 1 st October 2017 Expiry Date: 30 th September 2019

Patient Group Direction for Aspirin 300mg Version: 02 Start Date: 1 st October 2017 Expiry Date: 30 th September 2019 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG, Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire

More information

PATIENT GROUP DIRECTION (PGD) FOR Metronidazole 400mg Tablets

PATIENT GROUP DIRECTION (PGD) FOR Metronidazole 400mg Tablets Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This

More information

NHS Fife. Patient Group Direction for Named Community Pharmacists to Supply

NHS Fife. Patient Group Direction for Named Community Pharmacists to Supply Patient Group Direction for Named Community Pharmacists to Supply Senna tablets 7.5mg or Senna syrup 7.5mg/5ml (Total sennosides calculated as sennoside B) For patients aged 16 years and older prescribed

More information

Expiry Date: January 2009 Template Version: Page 1 of 7

Expiry Date: January 2009 Template Version: Page 1 of 7 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria: Cautions/Need for

More information

SUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION

SUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION SUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION GUIDANCE FOR PHARMACISTS ON SAFE SUPPLY TO PATIENTS (This

More information

National Emergency Medicine Programme. Protocol for the administration of Paracetamol (Acetaminophen) at Triage in the Emergency Department

National Emergency Medicine Programme. Protocol for the administration of Paracetamol (Acetaminophen) at Triage in the Emergency Department National Emergency Medicine Programme Protocol for the administration of Paracetamol (Acetaminophen) at Triage in the Emergency Date: November 2016 Table of Contents 1.0 Critical Elements... 3 2.0 Clinical

More information

Croydon Health Services NHS Trust (Working in Partnership) Shared Care Guideline: Prescribing Agreement

Croydon Health Services NHS Trust (Working in Partnership) Shared Care Guideline: Prescribing Agreement Shared Care Guideline: Prescribing Agreement Section A: To be completed by the hospital consultant initiating the treatment GP Practice Details: Name: Address: Tel no: Fax no: NHS.net e-mail: Consultant

More information

Consultation Group: See relevant page in the PGD. Signature: 1. Review Date: November 2019

Consultation Group: See relevant page in the PGD. Signature: 1. Review Date: November 2019 NHS...... Grampian Patient Group Direction For The Supply Of Aciclovir For The Treatment Of Herpes Zoster (Shingles) Infection By Banff Area Community Pharmacists Working Within NHS Grampian (Pilot Project)

More information

Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 2

Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 2 Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 2 Date protocol prepared: October 2017 Date protocol due for review: October 2019 Expiry date: October

More information

PATIENT GROUP DIRECTION. Hepatitis A + B Vaccine (Twinrix, Twinrix paediatric, Ambirix )

PATIENT GROUP DIRECTION. Hepatitis A + B Vaccine (Twinrix, Twinrix paediatric, Ambirix ) PATIENT GROUP DIRECTION Administration of: By: Practice Nurses Hepatitis A + B Vaccine (Twinrix, Twinrix paediatric, Ambirix ) In: General Practice It is the responsibility of the professional working

More information

GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE MOUTH ULCERS. Version 4 December 2017

GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE MOUTH ULCERS. Version 4 December 2017 GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE MOUTH ULCERS Version 4 December 2017 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES December 2020 EXECUTIVE SPONSOR Chief Nurse

More information

NHS Greater Glasgow & Clyde Patient Group Direction (PGD) for Healthcare Professionals Typhoid vaccine (intra muscular administration)

NHS Greater Glasgow & Clyde Patient Group Direction (PGD) for Healthcare Professionals Typhoid vaccine (intra muscular administration) GG&C PGD ref no: 2017/1523 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation in adults

More information

PATIENT GROUP DIRECTION (PGD) FOR Amoxicillin 250mg/5ml Suspension

PATIENT GROUP DIRECTION (PGD) FOR Amoxicillin 250mg/5ml Suspension Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This

More information

Document Details. notification of entry onto webpage

Document Details.  notification of entry onto webpage Document Details Title Patient Group Direction (PGD) Administration of sodium chloride 0.9% injection by registered professionals Trust Ref No 1987-38096 Local Ref (optional) Main points the document As

More information

GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE INDIGESTION. Version 5 December 2017

GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE INDIGESTION. Version 5 December 2017 GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE INDIGESTION Version 5 December 2017 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES December 2020 EXECUTIVE SPONSOR Chief Nurse MAUP

More information

Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 1

Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 1 Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 Date protocol prepared: December 2015 Date protocol due for review: December 2017 This patient group direction

More information

IBUPROFEN PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline

IBUPROFEN PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline IBUPROFEN PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department and its

More information

Patient Group Direction (PGD) template

Patient Group Direction (PGD) template Patient Group Direction (PGD) template Initial supply of doxycycline 100mg capsules to adults and children aged eight (8) years and over exposed to a suspected biological agent Version no: 2014/2 Valid

More information

PATIENT GROUP DIRECTION FOR AZITHROMYCIN

PATIENT GROUP DIRECTION FOR AZITHROMYCIN Staff Characteristics Pharmacist registered with the RPSGB who has undertaken relevant training as specified by NHS Bristol Has undertaken appropriate training to carry out clinical assessment of patient

More information

Newfoundland and Labrador Pharmacy Board

Newfoundland and Labrador Pharmacy Board Newfoundland and Labrador Pharmacy Board Standards of Practice Prescribing by Pharmacists August 2015 Table of Contents 1) Introduction... 1 2) Requirements... 1 3) Limitations... 1 4) Operational Standards...

More information

Consultation Group: See relevant page in the PGD. Review Date: May Expiry Date: May 2020

Consultation Group: See relevant page in the PGD. Review Date: May Expiry Date: May 2020 NHS...... Grampian Patient Group Direction For The Administration Of Lidocaine Hydrochloride 1% Injection As Infiltration Anaesthesia For Insertion/Removal Of Tunnelled Central Venous Catheters By Nurses/Radiographers

More information

Patient Group Direction For The Administration Of Sodium Chloride (0.9%) Via Nebulisation By Physiotherapists Working Within NHS Grampian

Patient Group Direction For The Administration Of Sodium Chloride (0.9%) Via Nebulisation By Physiotherapists Working Within NHS Grampian NHS Grampian Patient Group Direction For The Administration Of Sodium Chloride (0.9%) Via Nebulisation By Physiotherapists Working Within NHS Grampian Lead Author: Consultation Group: Approver: Highly

More information

GG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

GG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT GG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:

More information

Appendix 3 Cardiac Catheter Lab at Musgrove Park Hospital PATIENT GROUP DIRECTION (PGD)

Appendix 3 Cardiac Catheter Lab at Musgrove Park Hospital PATIENT GROUP DIRECTION (PGD) Appendix 3 Cardiac Catheter Lab at Musgrove Park Hospital PATIENT GROUP DIRECTION (PGD) PGD for the supply/administration of: Lidocaine 1% and Adrenaline 1:200,000 Master document reference number: This

More information

Expiry Date: January 2009 Template Version: Page 1 of 7

Expiry Date: January 2009 Template Version: Page 1 of 7 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Patients who require an antihistamine

More information

PATIENT GROUP DIRECTION (PGD) FOR

PATIENT GROUP DIRECTION (PGD) FOR Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This

More information

Pharmacy, Medicines and You. Principal Pharmacist Pharmaceutical Services Deputy Director of Pharmacy and Medicines Management

Pharmacy, Medicines and You. Principal Pharmacist Pharmaceutical Services Deputy Director of Pharmacy and Medicines Management Pharmacy, Medicines and You Wendy Robertson Liz Kemp Caroline Hind Principal Pharmacist Pharmaceutical Services Principal Pharmacist Pharmaceutical Services Deputy Director of Pharmacy and Medicines Management

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Lenvatinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

NHS Lanarkshire Policy for the Availability of Unlicensed Medicines

NHS Lanarkshire Policy for the Availability of Unlicensed Medicines NHS Lanarkshire Policy for the Availability of Unlicensed Medicines Prepared by: NHS Lanarkshire Chief Pharmacist Endorsed by: Area Drug & Therapeutic Committee Previous Version/Date: Primary Policy Date:

More information

Template (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment

Template (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment Template (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment The PRN Purpose & Outcome Protocol (PRN POP) Background The term PRN (from

More information

PROCEDURE FOR THE ADMINISTRATION OF HOMELY REMEDIES IN COMMUNITY HOSPITALS

PROCEDURE FOR THE ADMINISTRATION OF HOMELY REMEDIES IN COMMUNITY HOSPITALS PROCEDURE FOR THE ADMINISTRATION OF HOMELY REMEDIES IN COMMUNITY HOSPITALS Document Details Title Procedure for the administration of Homely Remedies in Community Hospitals Trust Ref No 1896-36344 Local

More information

Pharmacy First is primarily a service to support and improve self-care.

Pharmacy First is primarily a service to support and improve self-care. Self-Care Service The Pharmacy First service is commissioned by to provide the local population with rapid access to a pharmacist who can give self-care advice on a range of minor ailments. This will release

More information

GG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

GG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT GG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Immunisation

More information

CLINICAL GUIDELINE FOR IPRATROPIUM BROMIDE NEBULISER INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline

CLINICAL GUIDELINE FOR IPRATROPIUM BROMIDE NEBULISER INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline CLINICAL GUIDELINE FOR IPRATROPIUM BROMIDE NEBULISER INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical

More information

PATIENT GROUP DIRECTION (PGD) FOR:

PATIENT GROUP DIRECTION (PGD) FOR: YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication For the treatment of genital Chlamydia and/or epidemiological

More information

Standard Operating Procedure for When required (PRN) medicines in care homes

Standard Operating Procedure for When required (PRN) medicines in care homes Standard Operating Procedure for When required (PRN) medicines in care homes Introduction All health and social care organisations are responsible for ensuring the safe management of all medicines. This

More information

Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES

Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE SECTION 9(a) UNLICENSED MEDICINES BACKGROUND and PURPOSE Under the Medicines Act 1968 (EEC Directive 65/65), a company

More information

Approval of Patient Group Direction

Approval of Patient Group Direction Notice to all staff: NHS Hertfordshire, Patient Group Directions (PGDs) may only be used by members of the healthcare professions named on the title page and only if each professional has individually

More information

This guideline is for nursing staff within the Pain Services assisting with the administration of botulinum toxin.

This guideline is for nursing staff within the Pain Services assisting with the administration of botulinum toxin. CLINICAL GUIDELINE FOR THE SAFE ADMINISTRATION OF BOTULINUM NEURO TOIN FOR INJECTION within the PAIN SERVICE. Botox and eomin (trade names) 1. Aim/Purpose of this Guideline This guideline is for nursing

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB. Patient s first names.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB. Patient s first names. Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM PAZOPANIB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas

More information

SMG OB/GYN Lake Lansing St. Johns Returning Patient Questionnaire (Please print clearly and Fill out Entirely)

SMG OB/GYN Lake Lansing St. Johns Returning Patient Questionnaire (Please print clearly and Fill out Entirely) SMG OB/GYN Lake Lansing St. Johns Returning Patient Questionnaire (Please print clearly and Fill out Entirely) Name: Former/ Maiden Name: Date of Birth: Age: Today s Date: *Language: Race: Ethnicity: *Do

More information

PATIENT AGREEMENT TO SYSTEMIC THERAPY: GENERIC CONSENT FORM. Patient s first names. Date of birth. Job title

PATIENT AGREEMENT TO SYSTEMIC THERAPY: GENERIC CONSENT FORM. Patient s first names. Date of birth. Job title Patient identifier/label: Page 1 of 5 GENERIC CONSENT FORM Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other identifier) Male Female Special requirements

More information

Martina Khundakar - Senior Clinical Pharmacist Teresa Barnes - Lead Clinical Pharmacist - Specialist Care. Timothy Donaldson, Trust Chief Pharmacist

Martina Khundakar - Senior Clinical Pharmacist Teresa Barnes - Lead Clinical Pharmacist - Specialist Care. Timothy Donaldson, Trust Chief Pharmacist Policy on Pharmacological Therapies Practice Guidance Note The use of Oral Anti-Cancer Medicines and Oral Methotrexate within - V03 V03 - Issued Issue 1 Dec 15 Planned review December 2018 PPT-PGN 09 Part

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Cabozantinib PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL NAME/STAMP:

More information

GG&C PGD ref no: 2018/1562 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

GG&C PGD ref no: 2018/1562 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT GG&C PGD ref no: 2018/1562 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation in adults

More information

NHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION)

NHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION) SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION) CONTENTS POLICY SUMMARY... 2 1. SCOPE... 4 2. AIM... 4 3. BACKGROUND... 4 4. POLICY STATEMENTS... 5 4.1. GENERAL STATEMENTS... 5 4.2 UNLICENSED

More information

Symptomatic Relief Policy Compiled by: Drug Adminstration Steering Group Date: July 2004 Review Date: July 2006

Symptomatic Relief Policy Compiled by: Drug Adminstration Steering Group Date: July 2004 Review Date: July 2006 Symptomatic Relief Policy Compiled by: Drug Adminstration Steering Group Date: July 2004 Review Date: July 2006 Drug Administration Steering Group 1 Index Page Introduction 3 Clinical Conditions to which

More information

PATIENT GROUP DIRECTION (PGD)

PATIENT GROUP DIRECTION (PGD) Reference: XXXXXXX PATIENT GROUP DIRECTION (PGD) Initial supply of doxycycline 100mg capsules to adults and children aged 8 years and over exposed to a known or suspected release of anthrax For the initial

More information

PLEASE NOTE. For more information concerning the history of these regulations, please see the Table of Regulations.

PLEASE NOTE. For more information concerning the history of these regulations, please see the Table of Regulations. PLEASE NOTE This document, prepared by the Legislative Counsel Office, is an office consolidation of this regulation, current to September 22, 2014. It is intended for information and reference purposes

More information

Prescribing and Medicines: Minor Ailments Service (MAS)

Prescribing and Medicines: Minor Ailments Service (MAS) Publication Report Prescribing and Medicines: Minor Ailments Service (MAS) April 2010 March 2011 Publication date 28 June 2011 Contents Contents... 1 About ISD... 2 Official Statistics... 2 Introduction...

More information

abcdefghijklmnopqrstu

abcdefghijklmnopqrstu NHS Circular: PCA (P)(2011) 6 Health and Healthcare Improvement Directorate Pharmacy and Medicines Division abcdefghijklmnopqrstu Dear Colleague ADDITIONAL PHARMACEUTICAL SERVICES MINOR AILMENT SERVICE

More information

The Newcastle Upon Tyne Hospitals NHS Foundation Trust. Unlicensed Medicines Policy

The Newcastle Upon Tyne Hospitals NHS Foundation Trust. Unlicensed Medicines Policy The Newcastle Upon Tyne Hospitals NHS Foundation Trust Unlicensed Medicines Policy Version.: 2.4 Effective From: 13 October 2016 Expiry Date: 13 October 2018 Date Ratified: 12 October 2016 Ratified By:

More information

Consultation Group: See relevant page in the PGD. Review Date: October Expiry Date: October 2019

Consultation Group: See relevant page in the PGD. Review Date: October Expiry Date: October 2019 Patient Group Direction For The Administration Of Medicines Included In The Sepsis Formulary To Adults With Suspected Sepsis By Registered Nurses Working In Community Hospitals Within NHS Grampian Lead

More information

Medication Administration Policy Community Health & Social Care

Medication Administration Policy Community Health & Social Care Medication Administration Policy Community Health & Social Care Social Care Workers Version 2 April 2016 For review April 2018 NHS SHETLAND DOCUMENT DEVELOPMENT COVERSHEET* Name of document Medication

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 + RITUXIMAB

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CHOP 21 + RITUXIMAB Patient identifier/label: Page 1 of 6 FORM CHOP 21 + RITUXIMAB Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE CONTINUOUS INFUSION

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM CYTARABINE CONTINUOUS INFUSION Patient identifier/label: Page 1 of 6 CYTARABINE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas Hospital King s College Hospital Lewisham Hospital

More information

NHS PCA (P) (2015) 17 ANNEX B. Specials Frequently Asked Questions for Community Pharmacy. Pre-authorisation:

NHS PCA (P) (2015) 17 ANNEX B. Specials Frequently Asked Questions for Community Pharmacy. Pre-authorisation: ANNEX B Specials Frequently Asked Questions for Community Pharmacy Pre-authorisation: Q: When do I need to seek authorisation? A: You need to seek authorisation for all Specials manufactured medicines

More information

SHARED CARE GUIDELINE: Unlicensed use of Mercaptopurine for the treatment of Inflammatory Bowel Disease.

SHARED CARE GUIDELINE: Unlicensed use of Mercaptopurine for the treatment of Inflammatory Bowel Disease. LINCOLNSHIRE CLINICAL COMMISSIONING GROUPS in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Unlicensed use of Mercaptopurine for the treatment of Inflammatory Bowel Disease.

More information

Penticton & District Community Resources Society. Child Care & Support Services. Medication Control and Monitoring Handbook

Penticton & District Community Resources Society. Child Care & Support Services. Medication Control and Monitoring Handbook Penticton & District Community Resources Society Child Care & Support Services Medication Control and Monitoring Handbook Revised Mar 2012 Table of Contents Table of Contents MEDICATION CONTROL AND MONITORING...

More information

Cyclophosphamide INFUSION Infusion 4 Plus

Cyclophosphamide INFUSION Infusion 4 Plus Cyclophosphamide Infusion Day DEPARTMENT OF RHEUMATOLOGY DAY CASE ADMISSION RECORD PATIENT DAY CASE BOOKING REQUEST To be completed by Consultant, Registrar requesting day case Admission Hospital No. Forename

More information

PARACETAMOL PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline

PARACETAMOL PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline PARACETAMOL PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department and its

More information

Participant Information Sheet Main Trial. ATAFUTI A Trial Investigating Alternative Treatments for Adult Female Urinary Tract Infection

Participant Information Sheet Main Trial. ATAFUTI A Trial Investigating Alternative Treatments for Adult Female Urinary Tract Infection (TO BE PRINTED ON LOCAL HEADED PAPER) Participant Information Sheet Main Trial ATAFUTI A Trial Investigating Alternative Treatments for Adult Female Urinary Tract Infection Version number v8 22-04-16 Ethics

More information

Save up to $4,000 a year?!

Save up to $4,000 a year?! Save up to $4,000 a year?! Indication and Usage HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is an immune globulin with a recombinant human hyaluronidase indicated

More information

Best Practice Guidance for GP Practices, Community Pharmacists and Care Home Providers

Best Practice Guidance for GP Practices, Community Pharmacists and Care Home Providers Medicines Management in Care Homes Best Practice Guidance for GP Practices, Community Pharmacists and Care Home Providers 1. Communication The care home manager, community pharmacist and GP surgery should

More information

PRESCRIBING SUPPORT TECHNICIAN:

PRESCRIBING SUPPORT TECHNICIAN: PRESCRIBING SUPPORT TEAM AUDIT: CARDURA XL (Updated Sept 09) DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Cardura XL is a once daily, extended release preparation of doxazosin

More information

Oral Ibrutinib (single agent)

Oral Ibrutinib (single agent) Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM IBRUTINIB Patient s surname/family name Patient s first names Date of birth Hospital Name: NHS number (or other

More information

PROCEDURE FOR IMMUNISATION

PROCEDURE FOR IMMUNISATION Issue History Issue Version Purpose of Issue/Description of Change Planned Review Date One To promote the safe administration of vaccines 2014 Named Responsible Officer:- Approved by Date Medicines Governance

More information

EMERGENCY CARE DISCHARGE SUMMARY

EMERGENCY CARE DISCHARGE SUMMARY EMERGENCY CARE DISCHARGE SUMMARY IMPLEMENTATION GUIDANCE JUNE 2017 Guidance for implementation This section sets out issues identified during the project which relate to implementation of the headings.

More information

Felpham Community College Medical Conditions in School Policy

Felpham Community College Medical Conditions in School Policy Felpham Community College Medical Conditions in School Policy The Governing Body of Felpham Community College adopted the Medical Conditions in School Policy on 6 July 2016. 1. Introduction Statement of

More information

Ogden City School District Allergy Health and Emergency Care Plan for School. School: Grade: School Year:

Ogden City School District Allergy Health and Emergency Care Plan for School. School: Grade: School Year: PARENTS: Please place student s picture here Ogden City School District Allergy Health and Emergency Care Plan for School Student Name: Student must avoid contact with known allergen. School staff must

More information

St Mary s Church of England Primary School. First Aid Policy

St Mary s Church of England Primary School. First Aid Policy St Mary s Church of England Primary School First Aid Policy 1. Aims To act safely, promptly and effectively with accidents and emergencies To use basic first aid equipment To maintain records on the nature

More information

SELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING

SELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING CLINICAL PROTOCOL SELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING RATIONALE Medication errors can cause unnecessary

More information

Medicine Management Policy

Medicine Management Policy INDEX Prescribing Page 2 Dispensing Page 3 Safe Administration Page 4 Problems & Errors Page 5 Self Administration Page 7 Safe Storage Page 8 Controlled Drugs Best Practice Procedure Page 9 Controlled

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine-Doxorubicin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL

More information

COMMUNITY PHARMACY MINOR AILMENTS SERVICE

COMMUNITY PHARMACY MINOR AILMENTS SERVICE COMMUNITY PHARMACY MINOR AILMENTS SERVICE SUPPORTING SELF-CARE OCTOBER 2010 CONTENTS Index Page No 1 Introduction 3 2 Service Specification 4 3 Consultation Procedure 7 4 Re-ordering Documentation 10 Appendices

More information

Medication Policy. Linked to National Quality Standards- Quality Area Two: Element Policy statement

Medication Policy. Linked to National Quality Standards- Quality Area Two: Element Policy statement Medication Policy Administering medication should be considered a high risk practice. Authority must be obtained from a parent or legal guardian before educators administer any medication (prescribed or

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DOCETAXEL + PREDNISOLONE. Patient s first names

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DOCETAXEL + PREDNISOLONE. Patient s first names Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM DOCETAXEL + PREDNISOLONE Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s

More information

Non-Medical Prescribing Passport. Reflective Log And Information

Non-Medical Prescribing Passport. Reflective Log And Information Non-Medical Prescribing Passport Reflective Log And Information Non-Medical Prescribing Continued Profession Development Log NMPs must refer to their regulatory bodies requirements for maintaining and

More information

Promoting Effective Immunisation Practice

Promoting Effective Immunisation Practice 4th Edition 2017 Contents Introduction 3 Who is the programme for? 3 Learning Outcomes 4 Notes for employers 4 Updating 5 Notes for students 6 What are the options for learning? 6 Brief overview of the

More information

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY:

PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: PATIENT AGREEMENT TO SYSTEMIC ANTI- CANCER THERAPY: Gemcitabine-Cisplatin PATIENT DETAILS PATIENT S SURNAME/FAMILY NAME: PATIENT S FIRST NAME(S): DATE OF BIRTH: NHS NUMBER: (or other identifier) HOSPITAL

More information

The Children s Hospital Children s Day Care Ward, Tom s Ward. Labial Adhesions. Information for parents and carers

The Children s Hospital Children s Day Care Ward, Tom s Ward. Labial Adhesions. Information for parents and carers The Children s Hospital Children s Day Care Ward, Tom s Ward Labial Adhesions Information for parents and carers What are labial adhesions? Labial adhesions (sometimes known as labial fusion) occur when

More information

Guidance for registered pharmacies preparing unlicensed medicines

Guidance for registered pharmacies preparing unlicensed medicines Guidance for registered pharmacies preparing unlicensed medicines May 2014 The text of this document (but not the logo and branding) may be reproduced free of charge in any format or medium, as long as

More information

CLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD)

CLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD) CLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD) DEFINITION A Patient Group Direction (PGD) is a specific written instruction for the supply and administration

More information